Bristol Myers Squibb (BMS) and ConcertAI have launched the latter’s new Digital Trial Software-as-a-Service solution for oncology, haematology, and urology.
The digital clinical trial solution leverages the real-world data of ConcertAI, IT infrastructure, digital technology, and a wide research site network.
It merges clinical research and practice for streamlining the identification of the patients, consent, IRB approval, and negotiating contracts.
This software aims to lower or remove the duplicative entry of data and the continuous monitoring of data allows clinical research professionals to direct their resources for patient care.
The platform also aids researchers in reconsidering ways for designing trials, recruitment criteria, and data collection standards required to commence trials that are quick to execute, cost-efficient, and have diverse patient populations and sites.
Leveraging digitalisation technologies that cut down the time and difficulty of identifying subjects and carrying out trials, the digital trial solutions are designed to merge well into the clinical workflows of healthcare practices.
This approach also helps the practices in efficiently finding patients who could be candidates for trials and which trial sites benefit from utilising various incorporated applications that simplify patient screening.
Bristol Myers Squibb Global Biometrics and Data Sciences senior vice-president Venkat Sethuraman said: “The Digital Trial Solution will allow us to accelerate access to innovative, lifesaving cancer medicines to patients.
“And we anticipate this approach will become BMS’ gold standard for oncology studies in the future.”
The latest development comes after ConcertAI and the National Cancer Institute Community Oncology Research Program (NCI NCORP)-designated Louisiana State University (LSU) Health New Orleans signed a collaboration to boost diversity in clinical trials.
This five-year alliance will aid in guaranteeing wider access to trials throughout the Gulf South region.
